Research

 

Planned research topics and programs

1. Registration number: 0120.0802098

“Development and improvement of the technology of cardiovascular system and endocrine organs treatment by cell and efferent therapy and donor haemo- components quality improvement”. Work schedule: 2007–2011.

2. Registration number: 02.740.11.0885

“Systemic mechanisms interaction study of normal haematopoietic stem cells and leukemic cells with bone marrow cell niche”. Work schedule: 2010–2012. This work is part of the grant agreement with the University of Heidelberg, Germany.

Independent research and current projects

1. Retrospective registry of patients with chronic myeloid leukemia of the Northwest region of the Russian Federation;

2. Prospective registry of patients with chronic myeloid leukemia of Saint-Petersburg and Leningrad region.

Work on these projects is carried out under the grant of European LeukemiaNet as a part of the program “The EUropean Treatment Outcome Study (EUTOS) for CML”:

European Organization for European LeukemiaNet was established in 2004 as part of the 6th  Framework Programme of the European Community. The Institute of Hematology of North-West Medical Research Centre is an active member of the European LeukemiaNet (ELN) (www.leukemia-net.org) since 2007. This organization brings together almost all the countries of Europe and studies the epidemiology, diagnosis and optimization of leukemia therapy; is engaged in young professionals training, organizing of special seminars, developing of European guidelines for leukemia diagnostics and treatment.

Federal North-West Medical Research Centre collaborates with ELN predominantly in the study and treatment of chronic myeloid leukemia (CML). Within the framework of EUTOS project with retrospective observational registry of patients with CML the Institute of Hematology actively cooperates with leading hematology clinics in St. Petersburg since 2008 (Russian Research Institute of Hematology and Blood Transfusion, Municipal Hospital N15, Pavlov State Medical University), Leningrad Region, the Republic of Komi, Republic of Karelia and the Murmansk region.

Such productive cooperation was continued in the second EUTOS project on a prospective register of patients with CML in Saint-Petersburg and Leningrad region. These projects allow to track the effectiveness, treatment results, and epidemiological aspects of the disease in the North-West region of Russia.

Since 2007, Federal North-West Medical Research Centre staff attends the events held by ELN: annual symposium on acute and chronic leukemia in Mannheim (Germany), as well as separate meetings of the working groups on the CML which are regularly held in Heidelberg (Germany) and in the framework of the world's major symposia of European and American Association of Hematology. In the course of these activities several reports on the work results were made: in July 2010 in Heidelberg, Director of the Institute of Hematology Andrey Yurievich Zaritskey presented the results of a prospective study of patients of the  Northwest region of Russia, and in October 2013 at the symposium “ELN Frontiers Meeting” in Vienna (Austria) the Institute presented a poster report on long-term results of targeted therapy of CML in the Northwest region of Russia.

ELN Events with the representatives of Federal North-West Medical Research Centre in 2010:

1. 01–03.02.2010 The 7th annual symposium European LeukemiaNet (Mannheim, Germany).

2. 17–18.05.2010 Symposium for Young Scientists: Treatment of CML: modern approaches and future prospects. (Naples, Italy).

3. 10.06.2010 Workshop at the symposium of the European Hematology Association (Barcelona, Spain).

4. 02–03.07.2010 Annual Symposium of the Working Group for the Study EuropeanLeukemiaNet chronic myeloid leukemia (Heidelberg, Germany).

5. 22–24.10.2010 ELN Symposium: Modern approaches to the treatment of CML, myelodysplastic syndrome and acute leukemia (Vienna, Austria).

6. 05.12.2010 Workshop at the symposium of the American Association of Hematology (Orlando, USA).

Clinical trials of the Institute of Hematology

  1. “Multicenter open-label to confirm the safety and efficacy of lenalidomide in combination with dexamethasone in previously treated patients with multiple myeloma”.
  2. “Exjade multicenter open-label of post-transfusion iron overload treatment in patients with myelodysplastic syndrome, thalassemia and other forms of anemia
  3. “Efficacy and safety of G-CSF (leykostim) for neutropenia induced by imatinib in patients in the chronic phase of chronic myeloid leukemia”.
  4. “Multicenter randomized open parallel-group phase III study of efficacy and safety of lenalidomide (Revlimid) compared with chlorambucil as first-line therapy for previously untreated elderly patients with B-cell chronic lymphocytic leukemia”.
  5. “Multicenter randomized double-blind placebo-controlled parallel-group phase III study of efficacy and safety of lenalidomide (Revlimid) as supportive therapy in patients with B-cell chronic lymphocytic leukemia after second-line therapy”.
  6. “Randomized double-blind placebo-controlled study of the efficacy and safety of romiplostim in patients with thrombocytopenia due to myelodysplastic syndrome (MDS), low or medium (1) risk level”.
  7. “International multicenter randomized double-blind trial of vorinostat (MK-0683) or placebo in combination with bortezomib in patients with multiple myeloma”.
  8. “Multicenter study of phase IV conducted in order to identify changes in marker gene expression in response to treatment of Bcr-Abl inhibitors in patients with blastic phase of chronic myelogenous leukemia with positive Philadelphia chromosome or acute lymphocytic leukemia with positive Philadelphia chromosome”.
  9. “LASOR Research. Randomized phase III study to compare imatinib dose optimization and nilotinib therapy in patients with chronic myeloid leukemia and suboptimal response to imatinib at standard dose”.
  10. “Prospective multicenter international registry of patients with chronic transfusion-dependent anemia and risk of transfusion hemosiderosis”.
  11. “Multicenter open-label to confirm the safety use of azacitidine in patients with myelodysplastic syndrome (category of intermediate-2 or high-risk) or acute myeloid leukemia who will receive at least 6 cycles of azacytidine therapy”.
  12. “Public safety extension study of romiplostim (formerly “AMG 531”) at its long-term use in patients with thrombocytopenia due to myelodysplastic syndrome”.
  13. “Randomized multicenter placebo-controlled double-blind study of the safety, tolerability, efficacy and immunogenicity of the vaccine V212 in patients who was planned for autologous bone marrow transplantation”.
  14. “Randomized multicenter placebo-controlled double-blind comparative study of the third phase with parallel-groups to study the efficacy and safety of pomalidomid in patients with myeloproliferative neoplasm associated with myelofibrosis and dependence on red cells transfusion”.